Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis.
Reads0
Chats0
TLDR
Glucocorticoids treatment delayed viral clearance in COVID-19 patients of being mild or moderate ill or taking a high dose, rather in those of being severe or critical ill orTaking low dose or pulse.Abstract:
Background Evidence of glucocorticoids on viral clearance delay of COVID-19 patients is not clear. Methods In this systematic review and meta-analysis, we searched for studies on Medline, Embase, EBSCO, ScienceDirect, Web of Science, Cochrane Library, and ClinicalTrials.gov from 2019 to April 20, 2021. We mainly pooled the risk ratios (RRs) and mean difference (MD) for viral clearance delay and did subgroup analyses by the severity of illness and doses of glucocorticoids. Results 38 studies with a total of 9572 patients were identified. Glucocorticoids treatment was associated with delayed viral clearance in COVID-19 patients (adjusted RR 1.52, 95% CI 1.29 to 1.80, I2 = 52%), based on moderate-quality evidence. In subgroup analyses, risk of viral clearance delay was significant both for COVID-19 patients being mild or moderate ill (adjusted RR 1.86, 95% CI 1.35 to 2.57, I2 = 48%), and for patients of being severe or critical ill (adjusted RR 1.59, 95% CI 1.23 to 2.07, I2 = 0%); however, this risk significantly increased for patients taking high doses (unadjusted RR 1.85, 95% CI 1.08 to 3.18; MD 7.19, 95% CI 2.78 to 11.61) or medium doses (adjusted RR 1.86, 95% CI 0.96 to 3.62, I2 = 45%; MD 3.98, 95% CI 3.07 to 4.88, I2 = 4%), rather those taking low doses (adjusted RR 1.38, 95% CI 0.94 to 2.02, I2 = 59%; MD 1.46, 95% CI -0.79 to 3.70, I2 = 82%). Conclusions Glucocorticoids treatment delayed viral clearance in COVID-19 patients of taking high doses or medium doses, rather in those of taking low doses of glucocorticoids.read more
Citations
More filters
Journal ArticleDOI
The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel
Mojca Jensterle,Rok Herman,Andrej Janez,Wael Al Mahmeed,Khalid Al-Rasadi,Kamila Al-Alawi,Maciej Banach,Yaj Banerjee,Antonio Ceriello,Mustafa Cesur,Francesco Cosentino,Massimo Galia,Su-Yen Goh,Sanjay Kalra,Péter Kempler,Nader Lessan,Paulo A. Lotufo,Nikolaos Papanas,Ali A. Rizvi,Raul D. Santos,Anca Pantea Stoian,Peter P. Toth,Vijay Viswanathan,Manfredi Rizzo +23 more
TL;DR: New insights into the complex regulation of the HPA axis reveal how well the body performs in its adaptive survival mechanism during a severe infection, such as SARS-CoV-2, and how many parameters might disbalance the outcomes of this adaptation.
Journal ArticleDOI
Corticosteroid Therapy in COVID-19 Associated With In-hospital Mortality in Geriatric Patients: A Propensity Matched Cohort Study
Valentine Lidou-Renault,E Baudouin,P. Courtois-Amiot,Céline Bianco,Hélène Esnault,Audrey Rouet,Margaux Baque,Charlotte Tomeo,Antonio Rainone,Sara Thietart,Romain Veber,Clementine Ayache,Marion Pépin,Carmelo Lafuente-Lafuente,Emmanuelle Duron,Pierre Cailleaux,D. Haguenauer,Nadège Lemarié,Elena Paillaud,Agathe Raynaud-Simon,Caroline Thomas,Jacques Boddaert,Lorène Zerah,H. Vallet +23 more
TL;DR: In this multicentric matched-cohort study of geriatric patients hospitalized for COVID-19, the use of corticosteroids was significantly associated with in-hospital mortality.
Journal ArticleDOI
GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection
Cheng Xiang Foo,Stacey Reanna Bartlett,Keng Yih Chew,Minh Dao Ngo,Helle Bielefeldt-Ohmann,Buddhika J. Arachchige,Benjamin Matthews,Sarah Reed,Ran Wang,Matthew J. Sweet,Lucy D. Burr,Kavita Bisht,Svetlana A. Shatunova,Jane E Sinclair,Rhys Parry,Yuanhao Yang,Jean-Pierre Levesque,Alexander A. Khromykh,Mette M. Rosenkilde,Kirsty R. Short,Katharina Ronacher +20 more
TL;DR: In this article , the authors identify the mechanisms that drive immune cell recruitment in the lung during viral respiratory infections and identify novel drug targets to reduce inflammation and disease severity, and provide the first preclinical evidence for the therapeutic benefit of targeting GPR183 during severe viral respiratory infection.
Journal ArticleDOI
Factors affecting the content of Ig G-antibodies to S-protein SARS-CoV-2 in the blood of reconvalescents after new coronaviral infection (COVID-19)
Evgeny V Kryukov,Vladimir V. Salukhov,Bogdan Kotiv,Dmitrii V. Ovchinnikov,Yu. V. Andreychuk,D G Denisov,Alexey Bogomolov,M.A. Kharitonov,Yu. V. Rudakov,Pavel S. Sadovnikov,A. A. Chugunov +10 more
TL;DR: The formation and maintenance of the level of neutralizing antibodies for 6 months depends on the severity of the disease, the gender and age of the patients, and the fact of using GCS, which must be taken into account when carrying out therapeutic and preventive measures.
Journal ArticleDOI
No effect of remdesivir or betamethasone on upper respiratory tract SARS-CoV-2 RNA kinetics in hospitalised COVID-19 patients: a retrospective observational study
B. Sourander,Lars-Magnus Andersson,Magnus Brink,Aylin Yilmaz,Nicklas Sundell,Emelie Marklund,Staffan Nilsson,Magnus Lindh,Josefina Robertson,Magnus Gisslén +9 more
TL;DR: Since SARS-CoV-2 RNA kinetics was not affected by treatment, repeated sampling from the upper respiratory tract cannot be used to evaluate treatment response, and clinical status at baseline was not correlated with time to viral clearance.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Meta-analysis of observational studies in epidemiology - A proposal for reporting
Donna F. Stroup,Jesse A. Berlin,Sally C. Morton,Ingram Olkin,G. D. Williamson,Drummond Rennie,Drummond Rennie,David Moher,Betsy Jane Becker,Theresa Ann Sipe,Stephen B. Thacker +10 more
TL;DR: A checklist contains specifications for reporting of meta-analyses of observational studies in epidemiology, including background, search strategy, methods, results, discussion, and conclusion should improve the usefulness ofMeta-an analyses for authors, reviewers, editors, readers, and decision makers.
Journal ArticleDOI
Dexamethasone in Hospitalized Patients with Covid-19
Peter Horby,Wei Shen Lim,Jonathan Emberson,M Mafham,Jennifer L Bell,Louise Linsell,Natalie Staplin,Christopher E. Brightling,Andrew Ustianowski,E Elmahi,B Prudon,Christopher A Green,Timothy Felton,David Chadwick,K Rege,C Fegan,Lucy C Chappell,Saul N. Faust,Thomas Jaki,Katie Jeffery,Alan A Montgomery,Kathryn M Rowan,Edmund Juszczak,J K Baillie,Richard Haynes,Martin J Landray +25 more
TL;DR: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Journal ArticleDOI
What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes.
Jun Zhang,Kai F. Yu +1 more
TL;DR: This work proposes a simple method to approximate a risk ratio from the adjusted odds ratio and derive an estimate of an association or treatment effect that better represents the true relative risk.